Partner Content Partner Content Orphan medicines, advances, access and affordability LONDON, UNITED KINGDOM, April 19th 2017:
News Call for focus on NHS during snap election Pharma calls for focus on health service as nation goes to the polls.
News NICE rejects Opdivo in head and neck cancer – before it gain... England and Wales’ cost effectiveness watchdog NICE has rejected Opdivo for use against advanced head and neck cancer in draft guidance – before the drug has even been given final Euro
Views & Analysis How healthcare professionals engage NICE online NICE is reaching out and engaging more via social media.
News Hospitals should be fined for failing to innovate - report Government must get tough to encourage innovation, say peers.
News Charities unite to oppose NICE rare disease rules MPs to discuss controversial plan in special debate.
News Ipsen' Bylvay fluffs its lines in biliary atresia trial Ipsen's IBAT inhibitor Bylvay has failed a trial in biliary atresia, a rare and serious liver disease that affects babies and has limited treatments.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
